These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 24797826)
1. Wnt-responsive cancer stem cells are located close to distorted blood vessels and not in hypoxic regions in a p53-null mouse model of human breast cancer. Vadakkan TJ; Landua JD; Bu W; Wei W; Li F; Wong ST; Dickinson ME; Rosen JM; Lewis MT; Zhang M Stem Cells Transl Med; 2014 Jul; 3(7):857-66. PubMed ID: 24797826 [TBL] [Abstract][Full Text] [Related]
2. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer. Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438 [TBL] [Abstract][Full Text] [Related]
3. p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors. Chiche A; Moumen M; Romagnoli M; Petit V; Lasla H; Jézéquel P; de la Grange P; Jonkers J; Deugnier MA; Glukhova MA; Faraldo MM Oncogene; 2017 Apr; 36(17):2355-2365. PubMed ID: 27775073 [TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Schwab LP; Peacock DL; Majumdar D; Ingels JF; Jensen LC; Smith KD; Cushing RC; Seagroves TN Breast Cancer Res; 2012 Jan; 14(1):R6. PubMed ID: 22225988 [TBL] [Abstract][Full Text] [Related]
5. p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value. Santoro A; Vlachou T; Luzi L; Melloni G; Mazzarella L; D'Elia E; Aobuli X; Pasi CE; Reavie L; Bonetti P; Punzi S; Casoli L; Sabò A; Moroni MC; Dellino GI; Amati B; Nicassio F; Lanfrancone L; Pelicci PG Cell Rep; 2019 Jan; 26(3):624-638.e8. PubMed ID: 30650356 [TBL] [Abstract][Full Text] [Related]
6. Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway. Won HY; Lee JY; Shin DH; Park JH; Nam JS; Kim HC; Kong G FASEB J; 2012 Dec; 26(12):5002-13. PubMed ID: 22954590 [TBL] [Abstract][Full Text] [Related]
7. Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-α status. Harrison H; Rogerson L; Gregson HJ; Brennan KR; Clarke RB; Landberg G Cancer Res; 2013 Feb; 73(4):1420-33. PubMed ID: 23248117 [TBL] [Abstract][Full Text] [Related]
9. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Herschkowitz JI; Zhao W; Zhang M; Usary J; Murrow G; Edwards D; Knezevic J; Greene SB; Darr D; Troester MA; Hilsenbeck SG; Medina D; Perou CM; Rosen JM Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2778-83. PubMed ID: 21633010 [TBL] [Abstract][Full Text] [Related]
10. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Vaillant F; Asselin-Labat ML; Shackleton M; Forrest NC; Lindeman GJ; Visvader JE Cancer Res; 2008 Oct; 68(19):7711-7. PubMed ID: 18829523 [TBL] [Abstract][Full Text] [Related]
11. Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells. Kai K; Iwamoto T; Kobayashi T; Arima Y; Takamoto Y; Ohnishi N; Bartholomeusz C; Horii R; Akiyama F; Hortobagyi GN; Pusztai L; Saya H; Ueno NT Oncogene; 2014 Jan; 33(4):440-8. PubMed ID: 23376849 [TBL] [Abstract][Full Text] [Related]
12. LGR4 modulates breast cancer initiation, metastasis, and cancer stem cells. Yue Z; Yuan Z; Zeng L; Wang Y; Lai L; Li J; Sun P; Xue X; Qi J; Yang Z; Zheng Y; Fang Y; Li D; Siwko S; Li Y; Luo J; Liu M FASEB J; 2018 May; 32(5):2422-2437. PubMed ID: 29269400 [TBL] [Abstract][Full Text] [Related]
13. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Gunther EJ; Moody SE; Belka GK; Hahn KT; Innocent N; Dugan KD; Cardiff RD; Chodosh LA Genes Dev; 2003 Feb; 17(4):488-501. PubMed ID: 12600942 [TBL] [Abstract][Full Text] [Related]
14. Remodeling of endogenous mammary epithelium by breast cancer stem cells. Parashurama N; Lobo NA; Ito K; Mosley AR; Habte FG; Zabala M; Smith BR; Lam J; Weissman IL; Clarke MF; Gambhir SS Stem Cells; 2012 Oct; 30(10):2114-27. PubMed ID: 22899386 [TBL] [Abstract][Full Text] [Related]
15. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Conley SJ; Baker TL; Burnett JP; Theisen RL; Lazarus D; Peters CG; Clouthier SG; Eliasof S; Wicha MS Breast Cancer Res Treat; 2015 Apr; 150(3):559-67. PubMed ID: 25833208 [TBL] [Abstract][Full Text] [Related]
16. Cancer Stem Cells Regulate Cancer-Associated Fibroblasts via Activation of Hedgehog Signaling in Mammary Gland Tumors. Valenti G; Quinn HM; Heynen GJJE; Lan L; Holland JD; Vogel R; Wulf-Goldenberg A; Birchmeier W Cancer Res; 2017 Apr; 77(8):2134-2147. PubMed ID: 28202523 [TBL] [Abstract][Full Text] [Related]
17. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. Yan Y; Liu F; Han L; Zhao L; Chen J; Olopade OI; He M; Wei M J Exp Clin Cancer Res; 2018 Oct; 37(1):256. PubMed ID: 30340507 [TBL] [Abstract][Full Text] [Related]
18. Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells. Zhao Z; Lu P; Zhang H; Xu H; Gao N; Li M; Liu C Breast Cancer Res; 2014 Jul; 16(4):408. PubMed ID: 25056574 [TBL] [Abstract][Full Text] [Related]
19. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Zhang M; Behbod F; Atkinson RL; Landis MD; Kittrell F; Edwards D; Medina D; Tsimelzon A; Hilsenbeck S; Green JE; Michalowska AM; Rosen JM Cancer Res; 2008 Jun; 68(12):4674-82. PubMed ID: 18559513 [TBL] [Abstract][Full Text] [Related]
20. Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan. Gibby K; You WK; Kadoya K; Helgadottir H; Young LJ; Ellies LG; Chang Y; Cardiff RD; Stallcup WB Breast Cancer Res; 2012 Apr; 14(2):R67. PubMed ID: 22531600 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]